Healthy male pharmacokinetic study
In a human dose-escalation pharmacokinetic and pharmacodynamic study (8 healthy male subjects per dose level, 5 dose levels by intravenous infusion), ipamorelin produced dose-proportional pharmacokinetics (terminal half-life approximately 2 hours) and a single, time-limited episode of growth hormone release at every dose level tested, with an exponential decline back to negligible growth hormone concentration, consistent with preservation of the natural pulsatile growth hormone-release pattern rather than sustained elevation.
- Study type
- Human trial
- Population
- Human, healthy male volunteers, dose-escalation design, 8 subjects per dose level (5 dose levels)
- Source
- 1 Gobburu et al., 1999
Limitation: Single PK/PD study, healthy male subjects only (no female, elderly or clinical-population data identified), acute single-dose/short-infusion design rather than a repeated-dosing efficacy trial, not independently replicated.
Limitations in full
Single PK/PD study, healthy male subjects only (no female, elderly or clinical-population data identified), acute single-dose/short-infusion design rather than a repeated-dosing efficacy trial, not independently replicated. Evidence strength is rated Limited because this is a single study.